
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3098299/publications.pdf Version: 2024-02-01



TADA COMES

#	Article	IF	CITATIONS
1	Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada. Pain, 2022, 163, e129-e136.	4.2	3
2	Trends in Hospitalizations for Serious Infections Among People With Opioid Use Disorder in Ontario, Canada. Journal of Addiction Medicine, 2022, 16, 433-439.	2.6	16
3	Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. European Urology Focus, 2022, 8, 1433-1440.	3.1	5
4	The effects of COVIDâ€19 on the dispensing rates of antidepressants and benzodiazepines in Canada. Depression and Anxiety, 2022, 39, 156-162.	4.1	14
5	Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. JAMA Network Open, 2022, 5, e2143050.	5.9	1
6	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0
7	Comparisons of Insulin Spending and Price Between Canada and the United States. Mayo Clinic Proceedings, 2022, 97, 573-578.	3.0	2
8	Perioperative opioid-prescribing practices of resident trainees compared with staff surgeons. American Journal of Obstetrics and Gynecology, 2022, 226, 859-860.e2.	1.3	2
9	Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. International Journal of Drug Policy, 2022, 102, 103601.	3.3	22
10	Interprovincial variation in antibiotic use in Canada, 2019: a retrospective cross-sectional study. CMAJ Open, 2022, 10, E262-E268.	2.4	2
11	Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation. JAMA - Journal of the American Medical Association, 2022, 327, 846.	7.4	43
12	Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a populationâ€based propensityâ€score matched cohort study. Addiction, 2022, 117, 1972-1981.	3.3	9
13	Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors. Canadian Journal of Hospital Pharmacy, 2022, 75, 104-107.	0.1	1
14	Addressing the overdose crisis in North America with bold action. Addiction, 2022, 117, 1194-1196.	3.3	8
15	Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis. International Journal of Drug Policy, 2022, 103, 103644.	3.3	17
16	Evaluation of definitions for oral anticoagulant-associated major bleeding: A population-based cohort study. Thrombosis Research, 2022, 213, 57-64.	1.7	2
17	Opioid prescribing practices in chronic kidney disease: a population-based cohort study. Nephrology Dialysis Transplantation, 2022, 37, 2408-2417.	0.7	1
18	Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study. Canada Communicable Disease Report, 2022, 48, 170-178.	1.3	1

#	Article	IF	CITATIONS
19	The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study. Frontiers in Pharmacology, 2022, 13, 861953.	3.5	1
20	Uptake of biosimilar drugs in Canada: analysis of provincial policies and usage data. Cmaj, 2022, 194, E556-E560.	2.0	5
21	Identifying the changing age distribution of opioid-related mortality with high-frequency data. PLoS ONE, 2022, 17, e0265509.	2.5	1
22	Impact of acetaminophen product labelling changes in Canada on hospital admissions for accidental acetaminophen overdose: a population-based study. Cmaj, 2022, 194, E542-E548.	2.0	7
23	Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis. Drug and Alcohol Dependence, 2022, 236, 109459.	3.2	6
24	Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. International Journal of Drug Policy, 2022, 104, 103680.	3.3	6
25	Evaluating the populationâ€level effects of oxycodone restrictions on prescription opioid utilization in Ontario. Pharmacoepidemiology and Drug Safety, 2022, , .	1.9	1
26	International trends in prescription opioid sales among developed and developing economies, and the impact of the <scp>COVID</scp> â€19 pandemic: A crossâ€sectional analysis of 66 countries. Pharmacoepidemiology and Drug Safety, 2022, 31, 779-787.	1.9	5
27	Risk of suicide death following electroconvulsive therapy treatment for depression: a propensity score-weighted, retrospective cohort study in Canada. Lancet Psychiatry,the, 2022, 9, 435-446.	7.4	16
28	Impact of a publicly funded pharmacy-dispensed naloxone program on fatal opioid overdose rates: A population-based study. Drug and Alcohol Dependence, 2022, 236, 109473.	3.2	3
29	Categorization of Opioid Use Among Pregnant People and Association With Overdose or Death. JAMA Network Open, 2022, 5, e2214688.	5.9	5
30	Association of obstructive sleep apnea and opioids use on adverse health outcomes: A population study of health administrative data. PLoS ONE, 2022, 17, e0269112.	2.5	3
31	Metronidazole-associated Neurologic Events: A Nested Case-control Study. Clinical Infectious Diseases, 2021, 72, 2095-2100.	5.8	21
32	Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Canadian Journal of Public Health, 2021, 112, 89-96.	2.3	11
33	Patient-level Characteristics and Inequitable Access to Inpatient Electroconvulsive Therapy for Depression: A Population-based Cross-sectional Study: Caractéristiques au niveau du patient et accès inéquitable à la thérapie électroconvulsive pour patients hospitalisés. Canadian Journal of Psychiatry, 2021, 66, 147-158.	1.9	13
34	Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study. Clinical Infectious Diseases, 2021, 72, 279-284.	5.8	8
35	Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a populationâ€based time–series analysis. Addiction, 2021, 116, 1514-1520.	3.3	11
36	Sodiumâ€glucose coâ€transporterâ€2 inhibitors versus dipeptidyl peptidaseâ€4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. Diabetes, Obesity and Metabolism, 2021, 23, 950-960.	4.4	12

#	Article	IF	CITATIONS
37	Initial opioid prescription patterns and the risk of ongoing use and adverse outcomes. Pharmacoepidemiology and Drug Safety, 2021, 30, 379-389.	1.9	12
38	Potential Cost Implications of Mandatory Nonâ€Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada. Clinical Pharmacology and Therapeutics, 2021, 109, 739-745.	4.7	16
39	Medication use and its impact on high-cost health care users among older adults: protocol for the population-based matched cohort HiCOSTT study. CMAJ Open, 2021, 9, E44-E52.	2.4	2
40	Prevalence of Prenatal Opioid Exposure in Ontario, Canada, 2014-2019. JAMA Network Open, 2021, 4, e2037388.	5.9	14
41	Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA. Journal of General Internal Medicine, 2021, 36, 2601-2607.	2.6	9
42	Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada. Canadian Liver Journal, 2021, 4, 426-429.	0.9	4
43	Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. Cmaj, 2021, 193, E304-E309.	2.0	13
44	A qualitative study of a publicly funded pharmacy-dispensed naloxone program. International Journal of Drug Policy, 2021, 92, 103146.	3.3	16
45	Choppy waters: The importance of accounting for shifting drug utilization during the COVIDâ€19 pandemic in future observational drugâ€related studies. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 649-651.	2.5	4
46	Prescribing trends in direct-acting antivirals for the treatment ofÂhepatitis C in Ontario, Canada. Canadian Liver Journal, 2021, 4, 51-58.	0.9	5
47	Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada. BMJ Open, 2021, 11, e043586.	1.9	5
48	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 444-452.	0.9	2
49	Prescription opioid characteristics at initiation for non-cancer pain and risk of treated opioid use disorder: A population-based study. Drug and Alcohol Dependence, 2021, 221, 108601.	3.2	5
50	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. American Journal of Gastroenterology, 2021, 116, 1738-1740.	0.4	4
51	Adverse event rates associated with oral anticoagulant treatment early versus later after hospital discharge in older adults: a retrospective population-based cohort study. CMAJ Open, 2021, 9, E364-E375.	2.4	4
52	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. PLoS Medicine, 2021, 18, e1003590.	8.4	9
53	Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events. JAMA Network Open, 2021, 4, e218782.	5.9	20
54	A practical overview and decision tool for analyzing recurrent events in mental illness: A review. Journal of Psychiatric Research, 2021, 137, 7-13.	3.1	6

#	Article	IF	CITATIONS
55	Measuring the Burden of Opioid-Related Mortality in Ontario, Canada, During the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2112865.	5.9	54
56	Trends in Postpartum Opioid Prescribing: A Time Series Analysis. Clinical Pharmacology and Therapeutics, 2021, 110, 1004-1010.	4.7	3
57	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. American Journal of Preventive Medicine, 2021, 60, 831-839.	3.0	9
58	Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study. PLoS Medicine, 2021, 18, e1003631.	8.4	4
59	Opioid Prescribing Practices for Women Undergoing Elective Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2021, 28, 1325-1333.e3.	0.6	19
60	Measuring the impacts of the <i>Using Antibiotics Wisely</i> campaign on Canadian community utilization of oral antibiotics for respiratory tract infections: a time-series analysis from 2015 to 2019. Journal of Antimicrobial Chemotherapy, 2021, 76, 2472-2478.	3.0	7
61	Comparative effectiveness and safety of sodiumâ€glucose cotransporterâ€2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. Diabetes, Obesity and Metabolism, 2021, 23, 2320-2328.	4.4	12
62	Risk of serious medical events in patients with depression treated with electroconvulsive therapy: a propensity score-matched, retrospective cohort study. Lancet Psychiatry,the, 2021, 8, 686-695.	7.4	36
63	Impact of Clinical Practice Guidelines on Blood Glucose Test Strip Prescription Rates in Manitoba and Saskatchewan (Canada): An Interrupted Time-Series Analysis. Canadian Journal of Diabetes, 2021, 45, 557-565.e2.	0.8	1
64	Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada. Drug and Alcohol Dependence, 2021, 225, 108830.	3.2	9
65	Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects. Frontiers in Pharmacology, 2021, 12, 709349.	3.5	1
66	The association between prescription opioid dispensing and opioid-related morbidity and mortality in Ontario, Canada: an ecological study of public health units. Drug and Alcohol Dependence, 2021, 227, 108989.	3.2	7
67	Concordance between high antibiotic prescribing and high opioid prescribing among primary care physicians: a cross-sectional study. CMAJ Open, 2021, 9, E175-E180.	2.4	1
68	Identification of Prenatal Opioid Exposure Within Health Administrative Databases. Pediatrics, 2021, 147, .	2.1	7
69	Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults. JAMA Network Open, 2021, 4, e2130795.	5.9	17
70	Comparison of claims from high–drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis. CMAJ Open, 2021, 9, E1048-E1054.	2.4	0
71	Language proficiency and warfarin-related adverse events in older immigrants and Canadian residents: a population-based cohort study. Drugs and Therapy Perspectives, 2021, 37, 590-598.	0.6	1
72	New Opioid Use and Risk of Emergency Department Visits Related to Motor Vehicle Collisions in Ontario, Canada. JAMA Network Open, 2021, 4, e2134248.	5.9	3

#	Article	IF	CITATIONS
73	Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study. BMJ, The, 2021, 375, e066965.	6.0	15
74	Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. Epidemiology, 2021, Publish Ahead of Print, .	2.7	3
75	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. CMAJ Open, 2021, 9, E1181-E1186.	2.4	1
76	Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis. CMAJ Open, 2021, 9, E1055-E1062.	2.4	5
77	Extent of a valsartan drug shortage and its effect on antihypertensive drug use in the Canadian population: a national cross-sectional study. CMAJ Open, 2021, 9, E1128-E1133.	2.4	10
78	Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 444-452.	0.9	1
79	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. JAMA Internal Medicine, 2020, 180, 27.	5.1	41
80	Trends in opioid use before critical illness among elderly patients in Ontario. Journal of Critical Care, 2020, 55, 128-133.	2.2	1
81	Comprehensive Drug-Class Review Framework for improved evidence-based drug policy and formulary modernization. International Journal of Technology Assessment in Health Care, 2020, 36, 12-19.	0.5	5
82	Assessing the impact of an opioid prescribing guideline for dentists in Ontario, Canada. Journal of the American Dental Association, 2020, 151, 43-50.	1.5	6
83	One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis. Annals of Emergency Medicine, 2020, 75, 20-28.	0.6	19
84	Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value in Health, 2020, 23, 1137-1141.	0.3	14
85	Fallâ€Related Hospitalizations in Nursing Home Residents Coâ€Prescribed a Cholinesterase Inhibitor and Betaâ€Blocker. Journal of the American Geriatrics Society, 2020, 68, 2516-2524.	2.6	3
86	Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. Drug and Alcohol Dependence, 2020, 216, 108238.	3.2	9
87	New Opioid Use after Invasive Mechanical Ventilation and Hospital Discharge. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 568-575.	5.6	34
88	Effect of Academic Detailing on Promoting Appropriate Prescribing of Antipsychotic Medication in Nursing Homes. JAMA Network Open, 2020, 3, e205724.	5.9	12
89	The Role of the Medical School Training on Physician Opioid Prescribing Practices: Evidence from Ontario, Canada: Le rÃ1e de la formation à la faculté de médecine à l'égard des pratiques de prescription d'opioÃ⁻des des médecins: données probantes d'Ontario, Canada. Canadian Journal of Psvchiatry, 2020, 65, 710-720.	1.9	2
90	Opioid use and initiation of positive airway pressure treatment in adults referred for sleep disorder assessment: An explanatory population-based study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 194-204.	0.5	2

#	Article	IF	CITATIONS
91	Evaluation of opioid discontinuation after non-orthopaedic surgery among chronic opioid users: a population-based cohort study. British Journal of Anaesthesia, 2020, 124, 281-291.	3.4	14
92	Oxycodone, Hydromorphone, and the Risk of Suicide: A Retrospective Population-Based Case–Control Study. Drug Safety, 2020, 43, 737-743.	3.2	3
93	Characteristics of high–drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis. CMAJ Open, 2020, 8, E297-E303.	2.4	3
94	Evaluating the intended and unintended consequences of opioid-prescribing interventions on primary care in British Columbia, Canada: protocol for a retrospective population-based cohort study. BMJ Open, 2020, 10, e038724.	1.9	3
95	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. Canadian Journal of Diabetes, 2019, 43, 179-185.e1.	0.8	11
96	Healthcare resource utilization and costs among patients with direct oral anticoagulant or warfarin-related major bleeding. Thrombosis Research, 2019, 182, 12-19.	1.7	10
97	Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older—A Population-Based Cohort Study. JAMA Internal Medicine, 2019, 179, 1436.	5.1	6
98	The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study. PLoS ONE, 2019, 14, e0223589.	2.5	27
99	Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Network Open, 2019, 2, e1913304.	5.9	19
100	Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. CMAJ Open, 2019, 7, E582-E589.	2.4	14
101	"Like being put on an ice floe and shoved away― A qualitative study of the impacts of opioid-related policy changes on people who take opioids. International Journal of Drug Policy, 2019, 66, 15-22.	3.3	63
102	Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits. BMJ Open, 2019, 9, e026705.	1.9	16
103	Impact of delisting highâ€strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada. Pharmacoepidemiology and Drug Safety, 2019, 28, 726-733.	1.9	14
104	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. International Journal of Drug Policy, 2019, 66, 82-86.	3.3	8
105	Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study. BMJ Open, 2019, 9, e028125.	1.9	10
106	Incremental healthcare utilisation and costs among new senior high-cost users in Ontario, Canada: a retrospective matched cohort study. BMJ Open, 2019, 9, e028637.	1.9	6
107	Unplanned index hospital admissions among new older high-cost health care users in Ontario: a population-based matched cohort study. CMAJ Open, 2019, 7, E537-E545.	2.4	6
108	Understanding the Implications of a Shifting Opioid Landscape in Ontario. Healthcare Quarterly (Toronto, Ont), 2019, 22, 6-11.	0.5	16

#	Article	IF	CITATIONS
109	Rates of Infective Endocarditis in Substance Use Disorder and Associated Costs in Ontario. Canadian Journal of Addiction, 2019, 10, 36-43.	0.4	10
110	Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage. JAMA Network Open, 2019, 2, e1917053.	5.9	15
111	Do Diagnostic and Procedure Codes Within Population-Based, Administrative Datasets Accurately Identify Patients with Rectal Cancer?. Journal of Gastrointestinal Surgery, 2019, 23, 367-376.	1.7	0
112	Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario. Addiction, 2019, 114, 268-277.	3.3	5
113	Quality of primary care among individuals receiving treatment for opioid use disorder. Canadian Family Physician, 2019, 65, 343-351.	0.4	18
114	Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada. Neurourology and Urodynamics, 2018, 37, 1693-1700.	1.5	3
115	Trends and uptake of new formulations of controlled-release oxycodone in Canada. Pharmacoepidemiology and Drug Safety, 2018, 27, 520-525.	1.9	6
116	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. CMAJ Open, 2018, 6, E132-E138.	2.4	4
117	Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses. Journal of Bone and Mineral Research, 2018, 33, 419-429.	2.8	45
118	Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities. Canadian Journal of Psychiatry, 2018, 63, 361-369.	1.9	56
119	Opioid Use After ICU Admission Among Elderly Chronic Opioid Users in Ontario: A Population-Based Cohort Study. Critical Care Medicine, 2018, 46, 1934-1942.	0.9	13
120	Measuring the Burden of Opioid-related Mortality in Ontario, Canada. Journal of Addiction Medicine, 2018, 12, 418-419.	2.6	43
121	Regional variation in healthcare spending and mortality among senior high-cost healthcare users in Ontario, Canada: a retrospective matched cohort study. BMC Geriatrics, 2018, 18, 262.	2.7	14
122	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. Canadian Geriatrics Journal, 2018, 21, 269-273.	1.2	13
123	Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. Cmaj, 2018, 190, E1376-E1383.	2.0	21
124	Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ: British Medical Journal, 2018, 362, k3207.	2.3	103
125	Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. Pain, 2018, 159, 1562-1568.	4.2	60
126	Association between perioperative beta blocker use and cancer survival following surgical resection. European Journal of Surgical Oncology, 2018, 44, 1164-1169.	1.0	31

#	Article	IF	CITATIONS
127	The Burden of Opioid-Related Mortality in the United States. JAMA Network Open, 2018, 1, e180217.	5.9	484
128	A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride. BMC Musculoskeletal Disorders, 2018, 19, 160.	1.9	4
129	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 464-468.	0.9	2
130	Comparing the contribution of prescribed opioids to opioid-related hospitalizations across Canada: A multi-jurisdictional cross-sectional study. Drug and Alcohol Dependence, 2018, 191, 86-90.	3.2	24
131	Second-generation anti-depressants and risk of new-onset seizures in the elderly. Clinical Toxicology, 2018, 56, 1179-1184.	1.9	7
132	Opioid prescribing and adverse events in opioid-naive patients treated by emergency physicians versus family physicians: a population-based cohort study. CMAJ Open, 2018, 6, E110-E117.	2.4	14
133	Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA/LABA combination products: A population-based study. Respiratory Medicine, 2018, 143, 1-7.	2.9	5
134	Pregabalin and the Risk for Opioid-Related Death: A Nested Case–Control Study. Annals of Internal Medicine, 2018, 169, 732.	3.9	116
135	Fixed-dose combination antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study. PLoS Medicine, 2018, 15, e1002584.	8.4	82
136	Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies. Lancet Psychiatry,the, 2018, 5, 644-652.	7.4	83
137	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Annals of Allergy, Asthma and Immunology, 2018, 120, 59-65.e2.	1.0	18
138	Evaluation of Definitions for Oral Anticoagulant–Associated Major Bleeding: A Population-Based Cohort Study. Blood, 2018, 132, 426-426.	1.4	3
139	Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario. Health Promotion and Chronic Disease Prevention in Canada: Research, Policy and Practice, 2018, 38, 256-262.	1.1	10
140	Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada. Canadian Journal of Diabetes, 2017, 41, 138-142.	0.8	3
141	Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding. Chest, 2017, 152, 81-91.	0.8	68
142	Association Between Serotonergic Antidepressant Use During Pregnancy and Autism Spectrum Disorder in Children. JAMA - Journal of the American Medical Association, 2017, 317, 1544.	7.4	114
143	Lipophilic Î ² -Blockers and Suicide in the Elderly. Journal of Clinical Psychopharmacology, 2017, 37, 381-384.	1.4	4
144	Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. Drug Safety, 2017, 40, 835-840.	3.2	9

#	Article	IF	CITATIONS
145	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. Cmaj, 2017, 189, E4-E10.	2.0	41
146	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. BMJ Open, 2017, 7, e015686.	1.9	7
147	Pregabalin and heart failure: <scp>A</scp> populationâ€based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1087-1092.	1.9	13
148	More Rigorous Study Needed Before Claiming No Harm of Blood Glucose Test Strip Limits for Patients Using Insulin—Reply. JAMA Internal Medicine, 2017, 177, 890.	5.1	0
149	Impact of Unrestricted Access to Pregabalin on the Use of Opioids and Other CNS-Active Medications: A Cross-Sectional Time Series Analysis. Pain Medicine, 2017, 18, 1019-1026.	1.9	28
150	Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. Drug and Alcohol Dependence, 2017, 177, 315-321.	3.2	18
151	Prenatal Antidepressant Use and Autism Spectrum Disorder—Reply. JAMA - Journal of the American Medical Association, 2017, 318, 665.	7.4	2
152	Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. Drug and Alcohol Dependence, 2017, 179, 416-423.	3.2	18
153	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes. JAMA Internal Medicine, 2017, 177, 61.	5.1	15
154	The appropriateness and persistence of testosterone replacement therapy in Ontario. Pharmacoepidemiology and Drug Safety, 2017, 26, 119-126.	1.9	7
155	Changes in the dispensing of opioid medications in Canada following the introduction of a tamper-deterrent formulation of long-acting oxycodone: a time series analysis. CMAJ Open, 2017, 5, E800-E807.	2.4	25
156	Senior high-cost healthcare users' resource utilization and outcomes: a protocol of a retrospective matched cohort study in Canada. BMJ Open, 2017, 7, e018488.	1.9	6
157	Availability of naloxone in Canadian pharmacies:a population-based survey. CMAJ Open, 2017, 5, E779-E784.	2.4	20
158	Impact of a Graduated Approach on Opioid Initiation and Loss of Earnings Following Workplace Injury. Journal of Occupational and Environmental Medicine, 2017, 59, 1197-1201.	1.7	1
159	Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study. Canadian Urological Association Journal, 2017, 12, E142-5.	0.6	5
160	Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLoS Medicine, 2017, 14, e1002396.	8.4	362
161	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. Healthcare Policy, 2017, 13, 68-78.	0.6	2
162	First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Canadian Family Physician, 2017, 63, e277-e283.	0.4	8

#	Article	IF	CITATIONS
163	Trends in the use and cost of antipsychotics among older adults from 2007 to 2013: a repeated cross-sectional study. CMAJ Open, 2016, 4, E292-E297.	2.4	7
164	The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	4
165	High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study. PLoS ONE, 2016, 11, e0167479.	2.5	43
166	The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation. PLoS ONE, 2016, 11, e0149142.	2.5	29
167	Off-label use of inhaled tobramycin in Ontario, Canada. Thorax, 2016, 71, 862-864.	5.6	1
168	Opioid Use and Overdose: What We've Learned in Ontario. Healthcare Quarterly, 2016, 18, 8-11.	0.7	23
169	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 803-807.	1.4	0
170	Persistence of Antipsychotic Treatment in Elderly Dementia Patients: A Retrospective, Population-Based Cohort Study. Drugs - Real World Outcomes, 2016, 3, 175-182.	1.6	12
171	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. Canadian Journal of Diabetes, 2016, 40, 431-435.	0.8	11
172	Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population. Canadian Journal of Psychiatry, 2016, 61, 758-765.	1.9	20
173	Sensitivity and specificity of administrative mortality data for identifying prescription opioid–related deaths. Cmaj, 2016, 188, E67-E72.	2.0	19
174	Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. Canadian Journal of Cardiology, 2016, 32, 986.e17-986.e22.	1.7	21
175	Antiepileptic use for epilepsy and nonepilepsy disorders. Neurology, 2016, 86, 939-946.	1.1	29
176	Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study. Aging Male, 2016, 19, 90-95.	1.9	11
177	Varenicline and Risk of Self-Harm: A Nested Case-Control Study. PLoS ONE, 2016, 11, e0163681.	2.5	1
178	Opioid prescribing is a surrogate for inadequate pain management resources. Canadian Family Physician, 2016, 62, 465-8.	0.4	27
179	Evaluating the Effectiveness of First-Time Methadone Maintenance Therapy Across Northern, Rural, and Urban Regions of Ontario, Canada. Journal of Addiction Medicine, 2015, 9, 440-446.	2.6	42
180	Appropriate prescribing in nursing homes demonstration project (APDP) study protocol: pragmatic, cluster-randomized trial and mixed methods process evaluation of an Ontario policy-maker initiative to improve appropriate prescribing of antipsychotics. Implementation Science, 2015, 11, 45.	6.9	18

#	Article	IF	CITATIONS
181	A populationâ€based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors. British Journal of Clinical Pharmacology, 2015, 80, 662-669.	2.4	11
182	Triptans for Acute Migraine: Drug Class Review to Help Inform Policy Decisions. Headache, 2015, 55, 191-198.	3.9	4
183	Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis. CMAJ Open, 2015, 3, E428-E431.	2.4	9
184	Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Metaâ€Analysis. Headache, 2015, 55, 221-235.	3.9	197
185	Public Drug Coverage and Its Impact on Triptan Use Across <scp>C</scp> anada: A Populationâ€Based Study. Headache, 2015, 55, 212-220.	3.9	4
186	Access to Triptans for Acute Episodic Migraine: A Qualitative Study. Headache, 2015, 55, 199-211.	3.9	8
187	Retrospective analysis of trends in dispensing long-acting non-tamper-resistant oxycodone near the Canada-United States border. CMAJ Open, 2015, 3, E231-E235.	2.4	4
188	The impact of policies to reduce blood glucose test strip utilization and costs in Canada. Canadian Journal of Public Health, 2015, 106, e210-e216.	2.3	5
189	Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation. Stroke, 2015, 46, 1120-1122.	2.0	9
190	Neonatal opioid withdrawal and antenatal opioid prescribing. CMAJ Open, 2015, 3, E55-E61.	2.4	41
191	Prescription Stimulant Use and Hospitalization for Psychosis or Mania. Journal of Clinical Psychopharmacology, 2015, 35, 667-671.	1.4	20
192	Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. Annals of Family Medicine, 2015, 13, 343-346.	1.9	7
193	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Cmaj, 2015, 187, 174-180.	2.0	54
194	Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone. Cmaj, 2015, 187, E138-E143.	2.0	50
195	Safety of valproic acid in patients with chronic obstructive pulmonary disease: a populationâ€based cohort study. Pharmacoepidemiology and Drug Safety, 2015, 24, 256-261.	1.9	2
196	Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study. BMJ, The, 2015, 350, h2298-h2298.	6.0	115
197	Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open, 2015, 3, E166-E171.	2.4	154
198	Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. American Heart Journal, 2015, 170, 133-140.e3.	2.7	28

#	Article	IF	CITATIONS
199	Predictors of Opioid-Related Death During Methadone Therapy. Journal of Substance Abuse Treatment, 2015, 57, 30-35.	2.8	52
200	Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134550.	2.5	124
201	The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men. PLoS ONE, 2014, 9, e98003.	2.5	28
202	Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ, The, 2014, 349, g6196-g6196.	6.0	84
203	Reply to Strandberg and Tienari. Clinical Infectious Diseases, 2014, 58, 1043-1044.	5.8	1
204	Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. PLoS Medicine, 2014, 11, e1001736.	8.4	60
205	Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. BMJ Open, 2014, 4, e005377-e005377.	1.9	4
206	The Ontario Drug Policy Research Network: Bridging the gap between Research and Drug Policy. Health Policy, 2014, 117, 392-398.	3.0	15
207	Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. CMAJ Open, 2014, 2, E256-E261.	2.4	62
208	Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. Pharmacotherapy, 2014, 34, 9-18.	2.6	5
209	Upper Gastrointestinal Bleeding in Elderly Adults with Dementia Receiving Cholinesterase Inhibitors: A Populationâ€Based Cohort Study. Journal of the American Geriatrics Society, 2014, 62, 382-384.	2.6	10
210	The burden of premature opioidâ€related mortality. Addiction, 2014, 109, 1482-1488.	3.3	125
211	Risk of overdose and death following codeine prescription among immigrants. Journal of Epidemiology and Community Health, 2014, 68, 1057-1063.	3.7	7
212	Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study. Clinical Infectious Diseases, 2014, 58, 350-356.	5.8	45
213	Higher anti-depressant dose and major adverse outcomes in moderate chronic kidney disease: a retrospective population-based study. BMC Nephrology, 2014, 15, 79.	1.8	13
214	Altered mental status in older adults with histamine2-receptor antagonists: A population-based study. European Journal of Internal Medicine, 2014, 25, 701-709.	2.2	17
215	Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly. Journal of Bone and Mineral Research, 2014, 29, 2483-2488.	2.8	20
216	Temporal Trend of Carpal Tunnel Release Surgery: A Population-Based Time Series Analysis. PLoS ONE, 2014, 9, e97499.	2.5	21

#	Article	IF	CITATIONS
217	Adverse Cardiac Events in Older Patients Receiving Venlafaxine. Journal of Clinical Psychiatry, 2014, 75, e552-e558.	2.2	23
218	Trends in high-dose opioid prescribing in Canada. Canadian Family Physician, 2014, 60, 826-32.	0.4	85
219	Statin Toxicity From Macrolide Antibiotic Coprescription. Annals of Internal Medicine, 2013, 158, 869.	3.9	132
220	Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone. American Journal of Cardiology, 2013, 112, 420-423.	1.6	23
221	Risk of Acute Kidney Injury From Oral Acyclovir: A Population-Based Study. American Journal of Kidney Diseases, 2013, 61, 723-729.	1.9	42
222	No Increase in Adverse Events During Aliskiren Use Among Ontario Patients Receiving Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers. Canadian Journal of Cardiology, 2013, 29, 586-591.	1.7	14
223	Progression through diabetes therapies among new elderly users of metformin: a population-based study. Diabetic Medicine, 2013, 30, e51-e55.	2.3	5
224	Risk of incident diabetes among patients treated with statins: population based study. BMJ, The, 2013, 346, f2610-f2610.	6.0	338
225	Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. Cmaj, 2013, 185, 1035-1041.	2.0	18
226	Comparing two types of macrolide antibiotics for the purpose of assessing population-based drug interactions. BMJ Open, 2013, 3, e002857.	1.9	20
227	Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj, 2013, 185, E121-E127.	2.0	159
228	Trends in selection and timing of firstâ€line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006. Diabetic Medicine, 2013, 30, 1209-1213.	2.3	15
229	Opioid Dose and Risk of Road Trauma in Canada. JAMA Internal Medicine, 2013, 173, 196.	5.1	127
230	Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults. Annals of Internal Medicine, 2013, 158, 447.	3.9	88
231	Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: A retrospective cohort study. Clinical Toxicology, 2012, 50, 390-395.	1.9	30
232	The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly. Archives of Internal Medicine, 2012, 172, 1739.	3.8	159
233	Persistence With Therapy Among Patients Treated With Warfarin for Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 1687.	3.8	69
234	Oral bisphosphonate use in the elderly is not associated with acute kidney injury. Kidney International, 2012, 82, 903-908.	5.2	46

#	Article	IF	CITATIONS
235	Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dialysis Transplantation, 2012, 27, 1591-1598.	0.7	23
236	Long-term Analgesic Use: Sometimes Less Is Not More—Reply. Archives of Internal Medicine, 2012, 172, 1189.	3.8	3
237	Antidepressants, metoprolol and the risk of bradycardia. Therapeutic Advances in Psychopharmacology, 2012, 2, 43-49.	2.7	12
238	Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents. Journal of Oncology Practice, 2012, 8, 179-183.	2.5	10
239	Long-term Analgesic Use After Low-Risk Surgery. Archives of Internal Medicine, 2012, 172, 425.	3.8	669
240	Inviting Patients to Read Doctors' Notes. Annals of Internal Medicine, 2012, 156, 608.	3.9	50
241	Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cardiovascular Outcomes in Chronic Dialysis Patients: A Population-Based Cohort Study. Archives of Internal Medicine, 2012, 172, 591-3.	3.8	15
242	Selective Serotonin Reuptake Inhibitors and Pulmonary Arterial Hypertension. Chest, 2012, 141, 348-353.	0.8	16
243	A Population-Based Assessment of the Drug Interaction Between Levothyroxine and Warfarin. Clinical Pharmacology and Therapeutics, 2012, 92, 766-770.	4.7	17
244	Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a highâ€ r isk population. Diabetic Medicine, 2012, 29, 1524-1528.	2.3	22
245	Antidepressant use, serotonin transporter affinity, and reinfarction among patients receiving clopidogrel: a populationâ€based study. Pharmacoepidemiology and Drug Safety, 2012, 21, 1328-1333.	1.9	1
246	The impact of federal warnings on publically funded desmopressin utilization among children in Ontario. Journal of Pediatric Urology, 2012, 8, 249-253.	1.1	8
247	Comparative adherence to oxybutynin or tolterodine among older patients. European Journal of Clinical Pharmacology, 2012, 68, 1121-1121.	1.9	13
248	Use of other opioids during methadone therapy: a populationâ€based study. Addiction, 2012, 107, 776-780.	3.3	23
249	Comparative adherence to oxybutynin or tolterodine among older patients. European Journal of Clinical Pharmacology, 2012, 68, 97-99.	1.9	28
250	Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border. Open Medicine, 2012, 6, e141-5.	1.5	4
251	Relationship of asthma management, socioeconomic status, and medication insurance characteristics to exacerbation frequency in children with asthma. Annals of Allergy, Asthma and Immunology, 2011, 106, 17-23.	1.0	68
252	Risk of Serious Falls Associated With Oxybutynin and Tolterodine: A Population Based Study. Journal of Urology, 2011, 186, 1340-1344.	0.4	36

#	Article	IF	CITATIONS
253	Geographical Variation in Opioid Prescribing and Opioid-Related Mortality in Ontario. Healthcare Quarterly, 2011, 14, 22-24.	0.7	62
254	Orlistat and Acute Kidney Injury: An Analysis of 953 Patients. Archives of Internal Medicine, 2011, 171, 702.	3.8	60
255	Trimethoprim/sulfamethoxazoleâ€induced phenytoin toxicity in the elderly: a populationâ€based study. British Journal of Clinical Pharmacology, 2011, 71, 544-549.	2.4	26
256	Sevelamer Prescriptions After Reporting of the Dialysis Clinical Outcomes Revisited (DCOR) Trial Findings: An Analysis of 5,495 Patients Receiving Maintenance Dialysis in Ontario, Canada. American Journal of Kidney Diseases, 2011, 57, 357-359.	1.9	3
257	Hospital Admissions for Hyperkalemia With Trimethoprim-Sulfamethoxazole: A Cohort Study Using Health Care Database Codes for 393,039 Older Women With Urinary Tract Infections. American Journal of Kidney Diseases, 2011, 57, 521-523.	1.9	12
258	Ciprofloxacin-induced theophylline toxicity: a population-based study. European Journal of Clinical Pharmacology, 2011, 67, 521-526.	1.9	30
259	Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ: British Medical Journal, 2011, 343, d5228-d5228.	2.3	61
260	Preventing Pressure Ulcers in Long-term Care. Archives of Internal Medicine, 2011, 171, 1839.	3.8	56
261	Opioid Dose and Drug-Related Mortality in Patients With Nonmalignant Pain. Archives of Internal Medicine, 2011, 171, 686-91.	3.8	531
262	Opioids and Dose-Related Deaths—Association or Causation?—Reply. Archives of Internal Medicine, 2011, 171, 1687.	3.8	1
263	The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke. Stroke, 2011, 42, 128-132.	2.0	27
264	Impaired renal function modifies the risk of severe hypoglycaemia among users of insulin but not glyburide: a population-based nested case–control study. Nephrology Dialysis Transplantation, 2011, 26, 1888-1894.	0.7	29
265	The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. Cmaj, 2011, 183, 303-307.	2.0	69
266	Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario. Canadian Family Physician, 2011, 57, e92-6.	0.4	79
267	Trends in opioid use and dosing among socio-economically disadvantaged patients. Open Medicine, 2011, 5, e13-22.	1.5	67
268	Health status utilities and the impact of pressure ulcers in long-term care residents in Ontario. Quality of Life Research, 2010, 19, 81-89.	3.1	37
269	Trimethoprim-Sulfamethoxazole–Induced Hyperkalemia in Patients Receiving Inhibitors of the Renin-Angiotensin System. Archives of Internal Medicine, 2010, 170, 1045.	3.8	102
270	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ: British Medical Journal, 2010, 340, c693-c693.	2.3	358

#	Article	IF	CITATIONS
271	Blood glucose test strips: options to reduce usage. Cmaj, 2010, 182, 35-38.	2.0	33
272	Cost Minimal Effectiveness of SMBG. Canadian Journal of Diabetes, 2010, 34, 180.	0.8	0
273	Beta-Blockers, Trimethoprim-Sulfamethoxazole, and the Risk of Hyperkalemia Requiring Hospitalization in the Elderly. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1544-1551.	4.5	25
274	A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. Cmaj, 2009, 180, 713-718.	2.0	622
275	Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ: British Medical Journal, 2009, 339, b2942-b2942.	2.3	150
276	Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents. Pharmacoepidemiology and Drug Safety, 2009, 18, 756-760.	1.9	2
277	Macrolide-Induced Digoxin Toxicity: A Population-Based Study. Clinical Pharmacology and Therapeutics, 2009, 86, 383-386.	4.7	41
278	Toxic Megacolon in Children With Inflammatory Bowel Disease: Clinical and Radiographic Characteristics. American Journal of Gastroenterology, 2008, 103, 1524-1531.	0.4	44
279	Antipsychotic Therapy and Short-term Serious Events in Older Adults With Dementia. Archives of Internal Medicine, 2008, 168, 1090.	3.8	208
280	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. JAMA - Journal of the American Medical Association, 2007, 298, 2634.	7.4	303
281	Variation in Nursing Home Antipsychotic Prescribing Rates. Archives of Internal Medicine, 2007, 167, 676.	3.8	155